Radiation therapy plus osimertinib vs osimertinib alone in epidermal growth factor receptor mutated non-small cell lung cancer: A systematic review

Table 2 Quality assessment for randomized controlled trials (Cochrane risk of bias)

Ref.	Randomization process	Deviations from interventions	Missing outcome data	Measurement of outcomes	Selection of results	Overall risk
Soria et al[10], FLAURA	Low	Some concerns	Low	Low	Low	Some concerns
Ramalingam et al[9], FLAURA-OS	Low	Some concerns	Low	Low	Low	Some concerns
Reungwetwattana et al[24]	Low	Some concerns	Low	Low	Low	Some concerns
Cho et al[25], FLAURA Asian	Low	Some concerns	Low	Low	Low	Some concerns
Wu et al[11], AURA3-CNS	Low	Low	Low	Low	Low	Low
Brown et al[14], RTOG 0933	Low	Low	Some concerns	Low	Low	Some concerns
Brown et al[13], NCCTG N107C	Low	Low	Low	Low	Low	Low
Brown et al[15], SRS study	Low	Low	Low	Low	Low	Low
Jänne et al[26], FLAURA2-CNS	Low	Some concerns	Low	Low	Low	Some concerns
Li et al[19], FLOWERS	Low	Some concerns	Some concerns	Low	Low	Some concerns

Risk of bias assessment based on Cochrane RoB 2 tool. "Some concerns" primarily related to open-label study design in targeted therapy trials.